Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:40:33.647Z.
Calculation as of: 2026-10-06T13:40:33.647Z.
Quote observation: 2026-10-06T13:37:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e7d16b5ba5167ceff619aa020f317ca223699ac3cb4068fa61dc11e0d5c4076
PE RATIO
N/A
Market Cap
$4.54M
PE Ratio
N/A
TTM Avg
79.42
3Y Avg
79.42
5Y Avg
79.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.49M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.36M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.49M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.54M | N/A | 79.42 | 79.42 | 79.42 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.63M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.07M | N/A | 1.58 | 1.58 | 1.58 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.80M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.82M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.84M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.37
Forward EPS (Est.)
$-0.42
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
